Saudi Pharmaceutical Industries & Medical Appliances Corp.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. carries a market capitalization of 3.37B, placing it among publicly traded companies globally. Its enterprise value stands at 4.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Saudi Pharmaceutical Industries & Medical Appliances Corp.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. has 119.36M shares outstanding.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. trades at a trailing price-to-earnings ratio of 15.79. The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 2.00.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. trades at an EV/EBITDA multiple of 11.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Saudi Pharmaceutical Industries & Medical Appliances Corp. trades at an EV/FCF ratio of 24.65, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.61B versus a market cap of 3.37B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 78.63, indicating elevated leverage, while an interest coverage ratio of 4.37 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. posted a return on equity (ROE) of 13.43, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.69 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.84, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.78, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.51 indicates how many times Saudi Pharmaceutical Industries & Medical Appliances Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. recorded 18.70M in income tax expense. That works out to an effective tax rate of 7.71, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 242.41M, leaving 214.39M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp.'s stock has declined approximately 5.11% over the past 52 weeks. The 50-day moving average sits at 30.92, while the 200-day moving average is 29.69.

Over the twelve months ended June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. generated 1.74B in revenue and converted that into 214.39M in net income, yielding earnings per share of 1.87. EBITDA reached 388.64M, while operating income came in at 311.27M.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. holds 370.82M in cash and equivalents against 1.45B in total debt, resulting in a net debt position of 1.23B. Total book value stands at 1.69B, with working capital of 621.12M providing operational flexibility.

Saudi Pharmaceutical Industries & Medical Appliances Corp. produced 202.33M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -97.43M in capital expenditures, free cash flow totaled 104.90M - equivalent to 0.88 per share.

Over the twelve months ended June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. posted a gross margin of 50.97, reflecting its pricing power and cost economics. The operating margin of 17.91 and net profit margin of 12.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. paid dividends of 0.34 per share. The dividend payout ratio of 17.62 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Saudi Pharmaceutical Industries & Medical Appliances Corp. shareholders.

Saudi Pharmaceutical Industries & Medical Appliances Corp.'s most recent stock split took place on April 20, 2014 with a 17:26 split ratio.

As of June 30, 2026, Saudi Pharmaceutical Industries & Medical Appliances Corp. has an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.